N-(but-1-en-3-yl)hydroxylamine | 171095-35-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(but-1-en-3-yl)hydroxylamine
• 英文别名: 3-buten-2-hydroxylamine；N-but-3-en-2-ylhydroxylamine
• CAS: 171095-35-5
• 化学式: C₄H₉NO
• 分子量: 87.1216
• InChiKey: VRIDIEGYJUKQAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  6
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  叔丁基二甲基氯硅烷 、 N-(but-1-en-3-yl)hydroxylamine 在 咪唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Studies in 3-oxy-assisted 3-aza Cope rearrangements

  摘要：

  适当取代的N-硅氧基-N-烯丙基烯胺在热解条件下顺利发生3,3-σ同位素重排，生成相应的N-硅氧基亚氨基醚。

  DOI：

  10.1039/b200469k
• 作为产物：
  描述：

  [But-3-en-2-yl-[(2-methylpropan-2-yl)oxycarbonyl]amino] tert-butyl carbonate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 N-(but-1-en-3-yl)hydroxylamine
  参考文献：
  名称：

  Studies in 3-oxy-assisted 3-aza Cope rearrangements

  摘要：

  适当取代的N-硅氧基-N-烯丙基烯胺在热解条件下顺利发生3,3-σ同位素重排，生成相应的N-硅氧基亚氨基醚。

  DOI：

  10.1039/b200469k

文献信息

• Formation of<i>O</i>-Allyl Oximes by Reaction of Allylzinc Reagents with α-Chloronitroso Compounds
  作者：Norbert Sewald、Sorin V. Filip

  DOI：10.1055/s-2005-918429

  日期：——

  The reaction of α-chloronitrosocyclohexane with allyl­zinc reagents in THF selectively provides O-allylcyclohexanone oximes in very good yields in an ene type reaction followed by zinc halide elimination. N-Allyl hydroxylamines are formed as minor products via N-allyl nitrones when a nonpolar solvent, e.g. toluene, is employed. In both cases complete allylic transposition with respect to the allylic organozinc reagent is observed. Compared to non-metalated allyl compounds, which give N-allyl nitrones upon reaction with α-chloronitroso compounds, the use of zinc as hydrogen equivalent in an ene type reaction displays a drastic change of reactivity.

  α-氯亚硝基环己烷与烯丙基锌试剂在THF中反应，选择性地以很高的产率提供O-烯丙基环己酮肟，这是一种ene型反应，随后发生锌卤化物消除。当使用非极性溶剂（例如甲苯）时，会形成N-烯丙基羟肟作为少量产物，产物的形成途径是通过N-烯丙基亚硝酮。在这两种情况下，完全的烯丙基转位相对于烯丙基有机锌试剂被观察到。与非金属化的烯丙基化合物相比，后者在与α-氯亚硝基化合物反应时形成N-烯丙基亚硝酮，使用锌作为氢的等价物在ene型反应中显示出反应性发生了剧烈变化。
• Compounds and methods for the treatment of cardiovascular, inflammatory
  申请人：Cytomed, Inc.

  公开号：US05463083A1

  公开（公告）日：1995-10-31

  2,5-Diaryl tetrahydrofurans, 2,5-diaryl tetrahydrothiophenes, 1,3-diaryl cyclopentanes are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response. The compounds exhibit this biological activity by acting as PAF receptor antagonists, by inhibiting the enzyme 5-lipoxygenase, or by exhibiting dual activity, i,e., by acting as both a PAF receptor antagonist and inhibitor of 5-lipoxygenase. Also disclosed is a method to treat disorders mediated by PAF and/or leukotrienes that includes administering an effective amount of one or more of the above-identified compounds or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, to a patient in need of such therapy.

  揭示了能够减少中性粒细胞在炎症或免疫反应期间导致有害氧自由基形成的化合物，包括2,5-二芳基四氢呋喃、2,5-二芳基四氢噻吩、1,3-二芳基环戊烷。这些化合物通过作为PAF受体拮抗剂、抑制5-脂氧合酶酶或表现出双重活性（即既作为PAF受体拮抗剂又作为5-脂氧合酶抑制剂）来展示这种生物活性。还揭示了一种治疗由PAF和/或白三烯介导的疾病的方法，包括向需要此类治疗的患者投予上述化合物或其药学上可接受的盐中的一个或多个的有效量，可选地在药学上可接受的载体中。
• Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US06420392B1

  公开（公告）日：2002-07-16

  2,5-Diaryl tetrahydrofurans, 2,5-diaryl tetrahydrothiophenes, 1,3-diaryl cyclopentanes are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response. The compounds exhibit this biological activity by acting as PAF receptor antagonists, by inhibiting the enzyme 5-lipoxygenase, or by exhibiting dual activity, i.e., by acting as both a PAF receptor antagonist and inhibitor of 5-lipoxygenase. Also disclosed is a method to treat disorders mediated by PAF and/or leukotrienes that includes administering an effective amount of one or more of the above-identified compounds or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, to a patient in need of such therapy.

  披露了可以减少多形核白细胞在炎症或免疫反应期间引起化学趋化和呼吸爆发，从而导致有害氧自由基形成的2,5-二芳基四氢呋喃、2,5-二芳基四氢噻吩、1,3-二芳基环戊烷。这些化合物通过作为PAF受体拮抗剂、抑制酶5-脂氧合酶，或表现出双重活性，即作为PAF受体拮抗剂和5-脂氧合酶抑制剂来展示这种生物活性。还公开了一种治疗由PAF和/或白三烯介导的疾病的方法，包括向需要此类治疗的患者投予上述识别的一个或多个化合物或其药学上可接受的盐的有效量，可选地在药学上可接受的载体中。
• Studies in 3-oxy-assisted 3-aza Cope rearrangements
  作者：Mário J. S. Gomes、Lalit Sharma、Sundaresan Prabhakar、Ana M. Lobo、Paulo M. C. Glória

  DOI：10.1039/b200469k

  日期：——

  On thermolysis appropriately substituted N-silyloxy-N-allyl enamines undergo smooth 3,3-sigmatropic rearrangments to the corresponding N-silyloxy imino ethers.

  适当取代的N-硅氧基-N-烯丙基烯胺在热解条件下顺利发生3,3-σ同位素重排，生成相应的N-硅氧基亚氨基醚。